Characterization of Plasma Brain Natriuretic Peptide Level in Patients with Type 2 Diabetes

Inamori, Masahiko; Jimbu, Yumi; Hirata, Akihiko; Tominaga, Makoto

doi:10.1507/endocrj.52.353

Cited by 29 publications

(31 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A positive association between BNP level and UACR was found in a Japanese study of 316 patients with type 2 diabetes mellitus [6]. In a Japanese study of 233 patients with type 2 diabetes mellitus, BNP level was positively associated with macroalbuminuria [7]. These findings are in partial agreement with our results.…”

Section: Discussionsupporting

confidence: 91%

“…In previous epidemiological studies regarding the association BNP and renal function, plasma BNP ranged from 10.8 to 46.3 ng/dL [5][6][7][8][9]. The discrepancies among these studies may be explained, at least in part, by differences in sample size; the definition of renal function; characteristics such as age, sex, race, BMI, prevalence of coronary heart diseases, subclinical heart failure and hypertension; and other confounding factors.…”

Section: Discussionmentioning

confidence: 98%

“…BNP level was significantly positively associated with urinary albumin-creatinine ratio (UACR) in a Japanese study of patients with type 2 diabetes mellitus [6]. In a Japanese study of diabetic patients without coronary heart diseases, BNP level was positively associated with macroalbuminuria but not microalbuminuria [7]. On the other hand, in two Japanese studies of normotensive patients with type 2 diabetes mellitus, BNP level was not associated with either microalbuminuria [8] or proteinuria [9].…”

mentioning

confidence: 95%

See 2 more Smart Citations

B-type natriuretic peptide and renal function in Japanese patients with type 2 diabetes mellitus: The Dogo Study

et al. 2017

View full text Add to dashboard Cite

THE LEADING CAUSE OF THE DEATH among patients with renal dysfunction is cardiovascular diseases [1], and the importance of the interaction between the heart and kidneys is widely note [2]. Plasma B-type natriuretic peptide (BNP) releases from the ventricles in response to hemodynamic stress, and BNP is one of the predictive markers for cardiovascular events [3,4].Among patients with type 2 diabetes mellitus, sev- Abstract. Among patients with type 2 diabetes mellitus, the association between B-type natriuretic peptide (BNP) and renal function remains controversial. We therefore investigated this issue among Japanese patients with type 2 diabetes mellitus. This study included 687 Japanese patients with type 2 diabetes mellitus. BNP levels were divided at quartile points on the basis of the distribution. We used four outcomes regarding the renal function: 1) chronic kidney disease (CKD): estimated glomerular filtration rate (eGFR) < 60mL/min/1.72m 2 , 2) advanced CKD: eGFR < 30mL/min/1.72m 2 , 3) microalbuminuria: urinary albumin creatinine ratio (UACR) ≥ 30 mg/g creatinine, and 4) macroalbuminuria: UACR ≥ 300 mg/g creatinine. The prevalence values of CKD, advanced CKD, microalbuminuria, and macroalbuminuria were 27.4, 2.5%, 31.4%, and 9.3%, respectively. Highest BNP (≥ 39.2 ng/mL) was independently positively associated with microalbuminuria and macroalbuminuria (adjusted ORs, 2.61 [95% CI: 1.53-4.49] and 3.45 [95% CI: 1.46-8.72], respectively). High BNP was not associated with advanced CKD or CKD. There was a statistically significant positive exposure-response relationships between the BNP level and advanced CKD, microalbuminuria, and macroalbuminuria (p for trend = 0.047, 0.001, and 0.003, respectively). BNP level may be independently positively associated with advanced CKD, microalbuminuria, and macroalbuminuria but not CKD in Japanese patients with type 2 diabetes mellitus.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 98%

mentioning

confidence: 95%

See 1 more Smart Citation

B-type natriuretic peptide and renal function in Japanese patients with type 2 diabetes mellitus: The Dogo Study

et al. 2017

View full text Add to dashboard Cite

show abstract

“…11,12 However, those studies and current study data included patients with coronary heart disease (CHD). Recently, Igarashi et al 13 reported similar results for type 2 diabetic patients, but they observed no difference between patients with normoalbuminuria and those with microalbuminuria/ macroalbuminuria after excluding patients with CHD. Thus, in this study, multiple regression analysis was performed after excluding patients with CHD and cerebrovascular disease.…”

Section: Discussionmentioning

confidence: 86%

Morning home blood pressure may be a significant marker of nephropathy in Japanese patients with type 2 diabetes: ADVANCED-J study 1

et al. 2009

View full text Add to dashboard Cite

A 3-year multicenter, prospective, randomized, open-label trial (ADVANCED-J) compared the effect of an increased dose of angiotensin-II receptor blocker (ARB) with that of a maintenance dose of ARB plus calcium channel blocker (amlodipine) on blood pressure (BP) control, nephropathy and atherosclerosis in patients with type 2 diabetes and hypertension in whom the usual ARB dose failed to control BP. A cross-sectional analysis using baseline data was conducted. Of 316 patients (recruited between September 2004 and December 2005), 228 patients were evaluated by multiple regression analysis using two models after randomization and exclusions. Model 1 assessed 13 baseline variables (age, sex, estimated diabetes duration, estimated hypertension duration, HbA1c, brain natriuretic peptide (BNP), high-sensitive C-reactive protein (hsCRP), triglycerides (TGs), total cholesterol (TCHO), diabetic retinopathy (DMR), systolic morning home BP (HBP), diastolic morning HBP and brachialankle pulse wave velocity (baPWV)) for correlation with the urinary albumin creatinine excretion rate (UACR). In model 2, systolic and diastolic morning HBP was replaced by systolic and diastolic office BP. The systolic morning HBP and systolic office BP or diastolic morning HBP and diastolic office BP correlations were weak, but significant (r¼0.43 and 0.48, respectively). BNP, HbA1c, DMR and estimated diabetes duration were significantly correlated with UACR in both models 1 and 2. Although systolic office BP did not show a significant correlation with UACR in model 2, systolic morning HBP showed a significant correlation with UACR in model 1. Morning HBP, but not office BP, may be a significant marker of nephropathy in Japanese patients with type 2 diabetes.

show abstract

“…The values of FPG and IRI were also used to estimate the homeostasis model assessment insulin resistance (HOMA-IR) index 14) . In addition, compliance with the agent, including clinically adverse side-effects, was carefully checked, and the following parameters were measured each month: glutamic oxaloacetic transaminase (GOT), glutamic pyruvic transaminase (GPT), and lactate dehydrogenase (LDH) for hepatic dysfunction 10) ; and plasma brain natriuretic peptide (BNP) for fluid retention, peripheral edema, and congestive heart failure 15) . Furthermore, to evaluate the occurrence of edema by the agent, the edema index was measured using a body composition analyzer, InBody 3.0 ® (Biospace, Tokyo, Japan), at the beginning (Month 0) and end (Month 4) of the study.…”

Section: Protocol and Measurement Of Laboratory Parametersmentioning

confidence: 99%

Pioglitazone Reduces Atherogenic Outcomes in Type 2 Diabetic Patients

Inamori

Hirata

Yamaguchi

et al. 2008

JAT

Self Cite

View full text Add to dashboard Cite

Aim:The aim of this study was to evaluate the anti-atherogenic outcomes of pioglitazone, a thiazolidinedione derivative, in type 2 diabetic patients. Methods: Eight patients with poor diabetic control were treated with 15 mg of pioglitazone for 4 months. Blood samples were collected monthly, and the levels of fasting plasma glucose (FPG), HbA1c, and lipids, such as triglycerides, total cholesterol, low-density lipoprotein-cholesterol, and high-density lipoprotein-cholesterol, were measured. Other parameters, including immunorecative insulin (IRI), remnant-like particle-cholesterol (RLP-C), adiponectin, plasminogen activator inhibitor type 1 (PAI-1), tumor necrosis factor (TNF)-, leptin, brain natriuretic peptide (BNP), and highsensitivity (hs)-C-reactive protein (CRP), were examined at the beginning and end of the study. In addition, clinically adverse side-effects were evaluated. Results: Treatment with pioglitazone significantly decreased the levels of HbA1c, FPG, the homeostasis model assessment of insulin resistance (HOMA-IR) index, RLP-C, PAI-1, TNF-, and hs-CRP, but not the level, IRI, lipids, or leptin. In contrast, adverse side-effects, including body weight gain, liver dysfunction and edema, were not observed during this study. Conclusion: These results strongly suggested that treatment with pioglitazone has a greater clinical benefit for the prevention of atherosclerosis, including coronary heart diseases, without any adverse side-effects. J Atheroscler

show abstract

Characterization of Plasma Brain Natriuretic Peptide Level in Patients with Type 2 Diabetes

Cited by 29 publications

References 38 publications

B-type natriuretic peptide and renal function in Japanese patients with type 2 diabetes mellitus: The Dogo Study

B-type natriuretic peptide and renal function in Japanese patients with type 2 diabetes mellitus: The Dogo Study

Morning home blood pressure may be a significant marker of nephropathy in Japanese patients with type 2 diabetes: ADVANCED-J study 1

Pioglitazone Reduces Atherogenic Outcomes in Type 2 Diabetic Patients

Contact Info

Product

Resources

About